why choose us

300×250 Ad Slot

Research Article: Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L) Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study

Date Published: 2023-09-05

Introduction:
Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and the fourth leading cause of cancer death worldwide. Nearly half of HCC patients worldwide are from China. , Although surgical resection and liver transplantation may cure HCC, about % of HCC patients are already in the middle and late stages at the time of diagnosis due to insidious onset, and they are not suitable for radical surgery, leading to poor prognosis. – Transarterial chemoembolization (TACE) is commonly used to treat…

Read more

300×250 Ad Slot